CME in Minutes: Education in Oncology & Hematology

Please visit answersincme.com/KNY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Barbara Melosky, MD, FRCPC; and Alyson Chin, RN, BScN, MN-ACNP(A). In this activity, experts in lung cancer discuss the management of adverse events associated with tyrosine kinase inhibitor use in patients with ALK-positive metastatic non–small-cell lung cancer. Upon completion of this activity, participants should be better able to: Identify ALK tyrosine kinase inhibitor (TKI)–related adverse events (AEs) among patients with ALK-positive (ALK+) metastatic non–small-cell lung cancer (mNSCLC); Apply strategies to effectively monitor and manage ALK TKI–related AEs to enhance treatment adherence in patients with ALK+ mNSCLC; and Outline multidisciplinary, patient-centered strategies to optimize care for patients receiving ALK TKIs for ALK+ mNSCLC.

Please visit answersincme.com/RVH860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vivien Brown, MDCM, CCFP, FCFP, MSCP. In this activity, an expert in menopause management in primary care discusses identification and treatment of menopause-related vasomotor symptoms (VMS). Upon completion of this activity, participants should be better able to: Integrate communication about menopause and VMS into routine patient encounters; Review treatment options for moderate to severe VMS, including NK receptor antagonists, with patients using a shared decision-making approach; and Formulate strategies for optimally monitoring patients who are receiving NK receptor antagonists for menopause-related VMS.

Please visit answersincme.com/JKK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Alison J. Birtle, FRCP, FRCR, MD; and Niklas Klümper, MD. In this activity, experts in oncology discuss systemic therapies for locally advanced and metastatic urothelial carcinoma. Upon completion of this activity, participants should be better able to: Assess the evidence for recommended systemic treatment regimens for patients with LA/mUC in the context of treatment guidelines; Propose appropriate patient assessment strategies to guide systemic therapy decisions; and Formulate individualized treatment strategies to optimize outcomes for patients with LA/mUC using recommended first-line systemic treatments.

Please visit answersincme.com/NDX860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Tycel J. Phillips, MD and Steven Horwitz, MD. In this activity, experts in B-cell and T-cell lymphomas discuss EZH inhibitors for non-Hodgkin lymphoma. Upon completion of this activity, participants should be better able to: Discuss the rationale for EZH inhibitors in relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL); Describe the clinical profiles of available and emerging EZH inhibitors; and Outline current and potential methods of optimizing EZH inhibitors in clinical practice based on available evidence.

Please visit answersincme.com/ZGK860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Amer Zeidan, MBBS, MHS. In this activity, an expert in myelodysplastic syndromes (MDS) discusses approaches to optimize management of anemia in lower-risk MDS. Upon completion of this activity, participants should be better able to: Translate the latest clinical trial data to the management of patients with lower-risk MDS; Evaluate evidence-based strategies for optimizing the use of available agents in lower-risk MDS; and Design treatment plans that effectively sequence available therapies in patients with lower-risk MDS.

Please visit answersincme.com/XUG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Sara A. Hurvitz, MD, FACP. In this activity, an expert in breast cancer discusses the evidence for TROP2-directed antibody-drug conjugates in metastatic triple-negative disease (mTNBC). Upon completion of this activity, participants should be better able to: Review the clinical impact of TROP2-directed antibody-drug conjugates (ADCs) for the management of mTNBC; Evaluate the clinical implications of the evidence exploring first-line use of TROP2 ADCs in combination with immunotherapy for mTNBC; and Develop an evidence-informed strategy that incorporates TROP2-directed ADCs and immunotherapy combinations into first-line management of mTNBC, where appropriate.

Please visit answersincme.com/GFY860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Vishal A. Patel, MD; and Jonathan S. Zager, MD, FACS, FSSO. In this activity, experts in cutaneous oncology discuss the evolving role of gene expression profiling (GEP) tests in refining risk assessment and supporting individualized, multidisciplinary management strategies for patients with melanoma. Upon completion of this activity, participants should be better able to: Identify the clinical rationale for using GEP tests to stratify the risk of disease progression in patients with cutaneous melanoma; Review the clinical evidence, including guideline-supported data, for GEP tests to stratify disease progression risk in patients with cutaneous melanoma; Formulate multidisciplinary strategies for incorporating the results of GEP tests into risk-based management of patients with cutaneous melanoma; and Outline patient-centered approaches to integrating GEP tests into the management of patients with cutaneous melanoma at risk of metastasis.

Please visit answersincme.com/860/103117485-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD and David Harpole, MD. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss current and emerging strategies for sequencing therapies beyond progression. Upon completion of this activity, participants should be better able to: Evaluate sequencing strategies for patients with advanced EGFR-mutated NSCLC following first-line progression, applying biologic insights and genomic testing to guide optimal therapy selection; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.

Please visit answersincme.com/860/2026-MC-002106-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by María-Victoria Mateos, MD, PhD; and Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO. In this activity, experts in multiple myeloma discuss evidence-based strategies to personalize frontline care with anti-CD38-based quadruplets in patients with newly diagnosed myeloma. Upon completion of this activity, participants should be better able to: Identify key clinical factors that inform tailored frontline treatment approaches in patients with NDMM; Evaluate the clinical implications of key data supporting evolving frontline treatment approaches with anti-CD38–based quadruplet regimens in patients with NDMM; and Outline evidence-based strategies to integrate emerging treatment approaches into the clinical workflow of patient care in NDMM.

Please visit answersincme.com/860/103117485-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; and Benjamin Levy, MD, FASCO. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss how tumor biology and genomic reassessment can guide sequencing after first-line progression. Upon completion of this activity, participants should be better able to: Evaluate sequencing strategies for patients with advanced EGFR-mutated NSCLC following first-line progression, applying biologic insights and genomic testing to guide optimal therapy selection; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.

Please visit answersincme.com/860/101707775-replay2 to participate, download slides and supporting materials, complete the post test, and get a certificate. [Presented by Erika Hamilton, MD, FASCO; Komal Jhaveri, MD, FACP, FASCO; and John Allen Piede, MD. In this activity, experts in breast cancer provide a practical, community-focused discussion on integrating ESR1 mutation testing, applying emerging data on novel endocrine therapies, such as SERDs, and personalizing treatment strategies for patients with HR+, HER2− advanced breast cancer. Upon completion of this activity, participants should be better able to: Integrate testing for ESR1 mutations at appropriate times into practice workflows in the treatment of patients with HR-positive, HER2-negative advanced breast cancer; Evaluate the clinical implications of the latest evidence for approved and late-stage emerging novel oral SERDs in patients with HR-positive, HER2-negative advanced breast cancer; and Apply multidisciplinary, patient-centered strategies for optimizing treatment outcomes with novel oral SERDs in patients with HR-positive, HER2-negative advanced breast cancer.

Please visit answersincme.com/860/101707775-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Erika Hamilton, MD, FASCO; Komal Jhaveri, MD, FACP, FASCO; and Eleonora Teplinsky, MD, FASCO. In this activity, experts in breast cancer provide a practical, community-focused discussion on integrating ESR1 mutation testing, applying emerging data on novel endocrine therapies, such as SERDs, and personalizing treatment strategies for patients with HR+, HER2− advanced breast cancer. Upon completion of this activity, participants should be better able to: Integrate testing for ESR1 mutations at appropriate times into practice workflows in the treatment of patients with HR-positive, HER2-negative advanced breast cancer; Evaluate the clinical implications of the latest evidence for approved and late-stage emerging novel oral SERDs in patients with HR-positive, HER2-negative advanced breast cancer; and Apply multidisciplinary, patient-centered strategies for optimizing treatment outcomes with novel oral SERDs in patients with HR-positive, HER2-negative advanced breast cancer.

Please visit answersincme.com/BXW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Katarzyna J. Jerzak, MD, MSc, FRCPC. In this activity, an expert in medical oncology reviews the optimal use of CDK4/6 inhibitors for the treatment of hormone receptor (HR)–positive/HER2-negative early and metastatic breast cancer based on the latest guidelines and long-term evidence. Upon completion of this activity, participants should be better able to: Define patient eligibility for CDK4/6 inhibitor therapy in hormone receptor (HR)–positive/HER2-negative early and metastatic breast cancer per the Research Excellence, Active Leadership (REAL) Canadian Breast Cancer Alliance recommendations; Evaluate long-term clinical evidence supporting CDK4/6 inhibitors with endocrine therapy in HR-positive/HER2-negative early and metastatic breast cancer; and Apply evidence-based, patient-centered strategies to optimize long-term management of HR-positive/HER2-negative early and metastatic breast cancer.

Please visit answersincme.com/860/103518989-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by John Strickler, MD and Chiara Cremolini, MD, PhD. In this activity, experts in metastatic colorectal cancer (mCRC) discuss real-world evidence and clinical insights related to durable responses and long-term benefits in later-line care. Upon completion of this activity, participants should be better able to: Propose treatment plans based on predictors of durable benefit and real-world evidence.

Please visit answersincme.com/860/MED-ONC-03814-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Neil D. Gross, MD, FACS; Nikhil I. Khushalani, MD; and Emily S. Ruiz, MD, MPH. In this activity, leading skin cancer experts guide an interactive, multidisciplinary case-based discussion on optimizing (neo)adjuvant immunotherapy for high-risk, resectable cutaneous squamous cell carcinoma (CSCC). Upon completion of this activity, participants should be better able to: Apply the latest clinical trial data and guideline recommendations to treatment planning for patients with high-risk, resectable CSCC; Recognize when to incorporate systemic neoadjuvant and adjuvant immunotherapy in patients with CSCC based on clinical and pathological features; and Propose strategies to optimize care for patients with high-risk CSCC through the evidence-based use of neoadjuvant and adjuvant immunotherapy within multidisciplinary care plans.

Please visit answersincme.com/860/102331945-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Elizabeth Smyth, MD, FRCP and Daniela Molena, MD. In this activity, experts in gastric/gastroesophageal junction adenocarcinoma discuss the latest evidence and practical strategies for optimizing the treatment of resectable gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma with perioperative immunotherapy. Upon completion of this activity, participants should be better able to: Evaluate the evidence supporting the integration of perioperative immunotherapy (IO) in the treatment of resectable gastric (G)/gastroesophageal junction (GEJ) adenocarcinoma; Analyze the role of biomarkers in decision-making for perioperative IO in resectable G/GEJ adenocarcinoma; and Outline multidisciplinary strategies for optimizing the care of patients receiving perioperative IO for resectable G/GEJ adenocarcinoma.

Please visit answersincme.com/860/103117485-replay1 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Prof. Solange Peters, MD, PhD; and Pasi A. Jänne, MD, PhD. In this activity, experts in EGFR-mutated advanced non–small-cell lung cancer (NSCLC) discuss practical strategies for optimizing first-line testing and treatment selection. Upon completion of this series, participants should be better able to: Interpret updated evidence and recommendations regarding first-line testing and treatment selection for patients with advanced EGFR-mutated NSCLC; and Discuss the role of emerging therapies in advanced EGFR-mutated NSCLC, applying insights from tumor biology to optimize sequential treatment decisions.

Please visit answersincme.com/860/101834101-replay to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Simpa S. Salami, MD, MPH; and Neal D. Shore, MD, FACS. In this activity, experts in prostate cancer discuss new evidence for individualized, evidence-based treatment strategies in metastatic hormone-sensitive disease. Upon completion of this activity, participants should be better able to: Evaluate the clinical implications of the most recent data informing the standard of care treatment options for mHSPC; Integrate patient-, disease-, and therapy-related factors to develop individualized, evidence-based treatment strategies for mHSPC; and Design patient-centered care approaches that balance the benefit and risk of treatment to optimize outcomes in mHSPC.

Please visit answersincme.com/TNM860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Richard Kim, MD. In this activity, an expert in oncology discusses when and how to sequence later-line and chemotherapy-free therapies in metastatic colorectal cancer (mCRC). Upon completion of this activity, participants should be better able to: Evaluate factors influencing a treatment switch from cytotoxic agents for patients with stable metastatic colorectal cancer (mCRC); Formulate practical approaches for transitioning from chemotherapy to tyrosine kinase inhibitor (TKI) treatment in later-line settings for patients with mCRC; and Describe strategies to prolong chemotherapy-free disease control with TKIs.

Please visit answersincme.com/KJW860 to participate, download slides and supporting materials, complete the post test, and get a certificate. Presented by Aman Chauhan, MD and Rhonda K. Yantiss, MD. In this activity, experts in medical oncology and pathology discuss identification and treatment of extrapulmonary neuroendocrine carcinomas and extrapulmonary neuroendocrine tumors. Upon completion of this activity, participants should be better able to: Differentiate extrapulmonary neuroendocrine carcinoma (EP-NEC) from extrapulmonary neuroendocrine tumors (EP-NETs); Identify diagnostic and pathological approaches to improve the recognition and accurate classification of EP-NEC and EP-NET; Evaluate emerging clinical data on DLL3-targeting bispecific TCE agents in the treatment of EP-NEC and EP-NET; and Formulate evidence-based strategies to integrate DLL3-targeting bispecific TCE therapies into evolving treatment paradigms for EP-NEC and EP-NET.